MDMA or 3,4-Methylenedioxymethamphetamine, often referred to as Ecstasy is in phase 3 clinical trials for PTSD.
- FDA has designated MDMA-assisted therapy for PTSD a Breakthrough Therapy.
- Phase 3 clinical trial of MDMA-assisted therapy demonstrated statistically significant improvement in PTSD symptoms after three sessions.
- MDMA has been administered to approximately 1,700 human subjects with only one serious adverse reaction.
Positive permanent effects are seen in the following areas according to research: PTSD, Eating Disorders, and Anxiety disorders.
Dr. Dunn has completed the rigorous clinical training to be a MDMA provider and will be offering treatment once it receives final clearance.